Research Analysts Set Expectations for VIGL FY2029 Earnings

Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) - Research analysts at Wedbush issued their FY2029 EPS estimates for shares of Vigil Neuroscience in a note issued to investors on Thursday, March 13th. Wedbush analyst L. Chico anticipates that the company will earn $1.40 per share for the year. Wedbush has a "Outperform" rating and a $13.00 price objective on the stock. The consensus estimate for Vigil Neuroscience's current full-year earnings is ($2.07) per share.

A number of other analysts have also commented on the company. JMP Securities reaffirmed a "market outperform" rating and issued a $22.00 price target on shares of Vigil Neuroscience in a research note on Tuesday, November 26th. HC Wainwright dropped their target price on shares of Vigil Neuroscience from $17.00 to $14.00 and set a "buy" rating for the company in a research report on Friday, March 14th. Guggenheim reiterated a "buy" rating on shares of Vigil Neuroscience in a research report on Friday, January 24th. Finally, William Blair started coverage on shares of Vigil Neuroscience in a research note on Wednesday, December 4th. They issued an "outperform" rating for the company. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Vigil Neuroscience currently has a consensus rating of "Buy" and an average target price of $16.25.

Vigil Neuroscience Trading Down 4.9 %

NASDAQ VIGL traded down $0.10 on Monday, hitting $1.84. The company's stock had a trading volume of 120,124 shares, compared to its average volume of 468,807. The firm has a market cap of $75.01 million, a P/E ratio of -0.89 and a beta of 1.82. Vigil Neuroscience has a 52-week low of $1.49 and a 52-week high of $6.06. The company's 50-day simple moving average is $2.35 and its 200 day simple moving average is $2.75.

Remove Ads

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last posted its earnings results on Thursday, March 13th. The company reported ($0.57) earnings per share for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.08).

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Cubist Systematic Strategies LLC lifted its holdings in shares of Vigil Neuroscience by 53.0% during the fourth quarter. Cubist Systematic Strategies LLC now owns 24,120 shares of the company's stock valued at $41,000 after purchasing an additional 8,358 shares during the last quarter. Jane Street Group LLC purchased a new position in Vigil Neuroscience during the fourth quarter valued at $83,000. Barclays PLC boosted its holdings in Vigil Neuroscience by 43.6% in the fourth quarter. Barclays PLC now owns 64,049 shares of the company's stock worth $109,000 after acquiring an additional 19,436 shares in the last quarter. Northern Trust Corp grew its stake in shares of Vigil Neuroscience by 29.0% in the fourth quarter. Northern Trust Corp now owns 64,737 shares of the company's stock worth $110,000 after acquiring an additional 14,572 shares during the last quarter. Finally, Two Sigma Advisers LP increased its holdings in shares of Vigil Neuroscience by 243.8% during the fourth quarter. Two Sigma Advisers LP now owns 69,100 shares of the company's stock valued at $117,000 after acquiring an additional 49,000 shares in the last quarter. 83.64% of the stock is owned by hedge funds and other institutional investors.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.